Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A

Biochemical and Biophysical Research Communications

Volumn 405, Issue 4, 2011, Pages 673-677

  Pellett, Sabine ^a   Tepp, William H ^a   Stanker, Larry H ^b   Band, Philip A ^c,d   Johnson, Eric A ^a   Ichtchenko, Konstantin ^c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b WESTERN REGIONAL RESEARCH CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Atoxic; Botulinum neurotoxin A (BoNT A); Clostridium botulinum; Delivery vehicle; Spinal cord cells; Trafficking

Indexed keywords

BOTULINUM TOXIN A; METALLOPROTEINASE; RECOMBINANT ATOXIC DERIVATIVE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLOGICAL ACTIVITY; CELL MIGRATION; CONTROLLED STUDY; CYTOSOLIC FRACTION; DIAPHRAGM; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; FEMALE; HEAVY CHAIN; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIGHT CHAIN; MOUSE; NERVE CELL CULTURE; NEUROMUSCULAR SYNAPSE; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE;

ANIMALS; BIOLOGICAL ASSAY; BOTULINUM TOXINS, TYPE A; CYTOSOL; FEMALE; MICE; MICE, INBRED ICR; NEUROMUSCULAR JUNCTION; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25;

CLOSTRIDIUM BOTULINUM;

EID: 79951946085     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.01.093     Document Type: Article

References (31)

1. E.A. Johnson, Clostridium botulinum and Clostridium tetani, in: S.P. Borriello, P.R. Murray, G. Funke (Eds.), Topley and Wilson's Microbiology and Microbial Infections, 8th ed., Hodder Arnold, London, United Kingdom, 2005, 1035-1088.
2. Gimenez D.F., Gimenez J.A. The typing of botulinal neurotoxins. Int. J. Food Microbiol. 1995, 27:1-9.
3. Montal M. Botulinum neurotoxin: a marvel of protein design. Annu. Rev. Biochem. 2010, 79:591-617.
4. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rev. 2000, 80(2):717-766.
5. Johnson E.A. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu. Rev. Microbiol. 1999, 53:551-575.
6. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006, 312(5773):592-596.
7. Fischer A., Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J. Biol. Chem. 2007, 282:29604-29611.
8. Fischer A., Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc. Natl. Acad. Sci. USA 2007, 104:10447-10452.
9. Montecucco C., Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 1994, 13:1-8.
10. Band P.A., Blais S., Neubert T.A., Cardozo T.J., Ichtchenko K. Recombinant derivatives of botulinum neurotoxin A engineered for trafficking studies and neuronal delivery. Protein Expr. Purif. 2010, 71(1):62-73.
11. Pellett S., Tepp W.H., Clancy C.M., Borodic G.E., Johnson E.A. A neuronal cell-based botulinum neurotoxin assay for highly sensitive and specific detection of neutralizing serum antibodies. FEBS Lett. 2007, 581(25):4803-4808.
12. Malizio C.J., Goodnough M.C., Johnson E.A. Purification of Clostridium botulinum type A neurotoxin. Methods Mol. Biol. 2000, 145:27-39.
13. C.L. Hatheway, Botulism, in: A. Balows, W.H. Hausler, M. Ohashi, M.A. Turano (Eds.), Laboratory Diagnosis of Infectious Diseases: Principles and Practice, 1988 Springer-Verlag, NewYork, pp. 111-133.
14. Schantz E.J., Kautter D.A. Standardized assay for Clostridium botulinum toxins. J. Assoc.Off. Anal. Chem. 1978, 61:96-99.
15. Stanker L.H., Merrill P., Scotcher M., Cheng L. Development and partial characterization of high-affinity monoclonal antibodies for Botlinum toxin type A. J. Immunol. Methods 2008, 336:1-8.
16. Dekleva M.L., DasGupta B.R., Sathyamoorthy V. Botulinum neurotoxin type A radiolabeled at either the light or the heavy chain. Arch. Biochem. Biophys. 1989, 274(1):235-240.
17. Bernocco S., Fondelli C., Matteoni S., Magnoni L., Gotta S., Terstappen G.C., Raggiaschi R. Sequential detergent fractionation of primary neurons for proteomics studies. Proteomics 2008, 8(5):930-938.
18. Reed L.J., Muench H. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 1938, 27:493-497.
19. Roux S., Colasante C., Saint Cloment C., Barbier J., Curie T., Girard E., Molgó J., Brûlet P. Internalization of a GFP-tetanus toxin C-terminal fragment fusion protein at mature mouse neuromuscular junctions. Mol. Cell. Neurosci. 2005, 30(4):572-582.
20. Dobrenis K., Joseph A., Rattazzi M.C. Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. Proc. Natl. Acad. Sci. USA 1992, 89(6):2297-2301.
21. Francis J.W., Hosler B.A., Brown R.H., Fishman P.S. CuZn superoxide dismutase (SOD-1): tetanus toxin fragment C hybrid protein for targeted delivery of SOD-1 to neuronal cells. J. Biol. Chem. 1995, 270(25):15434-15442.
22. Ichinose M., Liu X.H., Hagihara N., Youle R.J. Extracellular bad fused to toxin transport domains induces apoptosis. Cancer Res. 2002, 62(5):1433-1438.
23. Duggan M.J., Quinn C.P., Chaddock J.A., Purkiss J.R., Alexander F.C., Doward S., Fooks S.J., Friis L.M., Hall Y.H., Kirby E.R., Leeds N., Moulsdale H.J., Dickenson A., Green G.M., Rahman W., Suzuki R., Shone C.C., Foster K.A. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J. Biol. Chem. 2002, 277(38):34846-34852.
24. Francis J.W., Brown R.H., Figueiredo D., Remington M.P., Castillo O., Schwarzschild M.A., Fishman P.S., Murphy J.R., vanderSpek J.C. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J. Neurochem. 2000, 74(6):2528-2536.
25. Taki M., Shiota M., Taira K. Transglutaminase-mediated N- and C-terminal fluorescein labeling of a protein can support the native activity of the modified protein. Protein Eng. Des. Sel. 2004, 17(2):119-126.
26. Bade S., Rummel A., Reisinger C., Karnath T., Ahnert-Hilger G., Bigalke H., Binz T. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates. J. Neurochem. 2004, 91(6):1461-1472.
27. Smith T.J., Lou J., Geren I.N., Forsyth C.M., Tsai R., Laporte S.L., Tepp W.H., Bradshaw M., Johnson E.A., Smith L.A., Marks J.D. Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization. Infect Immun. 2005, 73(9):5450-5457.
28. Breidenbach M.A., Brunger A.T. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 2004, 432:925-929.
29. Kiyatkin N., Maksymowych A.B., Simpson L.L. Induction of an immune response by oral administration of recombinant botulinum toxin. Infect. Immun. 1997, 65:4586-4591.
30. Pier C.L., Tepp W.H., Bradshaw M., Johnson E.A., Barbieri J.T., Baldwin M.R. Recombinant holotoxoid vaccine against botulism. Infect. Immun. 2008, 76(1):437-442.
31. Webb R.P., Smith T.J., Wright P., Brown J., Smith L.A. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 2009, 27(33):4490-4497.